Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robust higher-order feedback feedforward ILC for networked nonlinear system with varying trial lengths, data dropouts and disturbances.

Scientific reports·2026
Same author

Dual-Physical-Field Nanocatalysis: Injectable Hydrogel Enables Piezo-Photothermal Synergy for Breast Cancer Therapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR<sup>+</sup>/HER2<sup>-</sup> metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China.

Translational breast cancer research : a journal focusing on translational research in breast cancer·2026
Same author

20-hydroxyecdysone promotes brain development via upregulating MMP2 expression during metamorphosis in Helicoverpa armigera.

PLoS genetics·2026
Same author

Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study.

The oncologist·2025
Same author

BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study.

Breast (Edinburgh, Scotland)·2025

Related Experiment Video

Updated: Jun 13, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

RANTES gene polymorphisms and asthma risk: A meta-analysis.

Yong-Gang Zhang1, Jin Huang, Jie Zhang

  • 1Department of Respiratory Medicine, West China Medical School of Sichuan University, Chengdu, China.

Archives of Medical Research
|May 1, 2010
PubMed
Summary

The RANTES gene -403G/A polymorphism is linked to an increased risk of atopic asthma. Further research is needed to explore gene interactions and environmental factors in asthma development.

More Related Videos

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

Related Experiment Videos

Last Updated: Jun 13, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

Area of Science:

  • Immunogenetics
  • Respiratory Medicine
  • Molecular Biology

Background:

  • RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) is a chemokine involved in inflammatory cell recruitment, particularly eosinophils.
  • Previous studies on RANTES gene polymorphisms and asthma susceptibility have yielded conflicting results.
  • Asthma is a complex respiratory disease influenced by genetic and environmental factors.

Purpose of the Study:

  • To conduct a meta-analysis investigating the association between RANTES gene polymorphisms and asthma risk.
  • To resolve conflicting findings from previous studies regarding RANTES polymorphisms and asthma susceptibility.
  • To identify potential genetic risk factors for asthma.

Main Methods:

  • A literature-based meta-analysis was performed, including tabular data from relevant studies published before November 30, 2009.
  • Ten case/control studies comprising 1706 asthma cases and 1685 controls were included.
  • Potential sources of heterogeneity were investigated.

Main Results:

  • No significant association was found between RANTES polymorphisms (-403G/A and -28C/G) and overall asthma risk in the combined analysis.
  • Subgroup analyses by ethnicity and age did not reveal significant associations for the -403G/A polymorphism.
  • The -403G/A polymorphism showed a significant association with asthma risk in atopic asthma patients (dominant model: OR=1.38, P=0.009).

Conclusions:

  • The RANTES gene -403G/A polymorphism may be a risk factor specifically for atopic asthma.
  • Further large-scale studies are required to examine gene-to-gene and gene-to-environment interactions influencing RANTES polymorphisms and asthma risk.
  • This meta-analysis highlights the importance of considering atopic status in genetic association studies of asthma.